Onyx Pharmaceuticals Inc

3031 Research Drive
Richmond, CA 94806

USA

Phone: (510) 222-9700
Fax: (510) 222-9758
Email: ir@onyx-pharm.com
Web Site: http://www.onyx-pharm.com/

A. Company Profile

Onyx Pharmaceuticals (NASDAQ:ONXX) is developing innovative small molecule cancer treatments based on a molecular understanding of cancer.

B. Products

Product Pipelines

1.      Nexavar

Nexavar is a novel multiple kinase inhibitor that targets proteins involved in both tumor cell proliferation and angiogenesis (the formation of new blood vessels to support cancer cell growth). Nexavar inhibits the enzyme RAF kinase, which is a critical component of the RAS pathway - an important cascade of chemical signals that controls cell division. Abnormal activation of the RAS pathway is believed to play an integral role in the genesis of many cancers. Additionally, Nexavar inhibits VEGFR-2 and PDGFR-ß, key receptors of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), which play important roles in angiogenesis. Nexavar also inhibits other tyrosine kinases such as c-KIT and FLT-3.

2.      ONYX-015

ONYX-015 is an adenovirus that has been engineered in the laboratory to replicate only in cancer cells with abnormalities in the p53 pathway. These abnormalities, or mutations, occur in most types of human cancer. When ONYX-015 infects these cancer cells, the viral growth cycle proceeds and the cancer cells are killed. New viruses are then released and infect neighboring cancer cells, killing those cells and perpetuating the selective cancer-killing cycle. In this way, the therapeutic effect of ONYX-015 is amplified.

4. PD332991

PD332991 is cyclin-dependent kinase inhibitor.